Cardiac surgeons throughout the United States, Canada and Europe turn to CryoLife, Inc. for a dependable alternative in reconstructive cardiac surgery. Since 1984, CryoLife, Inc. has been fulfilling the needs of the cardiac surgery medical community with a dedication to improve human kind through the advancements in biotechnology. Over 1,900 cardiac surgeons in over 1000 institutions worldwide have implanted more than 50,000 CryoLife preserved cardiac allografts and experienced the natural benefits of the CryoLife difference.

CryoLife's cryopreserved human allografts provide cardiac surgeons with a variety of preserved implantable tissues, such as aortic valves, pulmonary valves and patch materials for cardiac valve replacement and reconstructions. CryoValve^® aortic and pulmonary valves allow surgeons to experience the same handling and functional characteristics of autologous valves. Tailoring flexibility for complex reconstructions and a resistance to infection, unlike other stentless or stented valves, is another benefit of cryopreserved human heart valves. Young and active adults, women of childbearing years and children have experienced the life saving benefits of CryoLife cryopreserved cardiac allografts without the limitations of anticoagulation therapies. CryoValve has demonstrated a history of outstanding performance in adult patients which is supported by 20 years of actuarial data and experience that is uniquely CryoLife.

CryoValve^®

While there are many heart valves available today, few can offer the same benefits to heart valves recipients as the CryoLife CryoValve. Supported by actual clinical data and the experience of the medical community, cardiac surgeons and their patient's have been given a gift of life like no other. The characteristics of CryoValve make it an ideal replacement option with boundless repair flexibility while maintaining the appeal of a natural valve. CryoValve's dependable durability and resistance to infection has given surgeons a valuable option to perform life saving valve replacements and reconstructions that can offer patients the ability to resume an active life style without anticoagulant limitations and a minimal risk for re-infection. For the past 20 years, CryoLife has offered surgeons the unequaled quality and performance of the aortic and pulmonary valves for valve replacement and root reconstruction options, Ross procedures, and more.

CryoVein^®

CryoLife cryopreserves human saphenous veins, superficial femoral veins and arteries, and aortoiliac grafts. The Company's cryopreserved vascular human tissue is used in central and peripheral vascular reconstruction surgeries. CryoLife has been cryopreserving human saphenous veins since 1986, providing cardiovascular and vascular surgeons with an important conduit alternative in bypass procedures. Since the mid-1980's, cardiovascular and vascular surgeons have implanted over 30,000 vascular grafts cryopreserved by CryoLife. CryoLife cryopreserved vascular grafts provide vascular surgeons with an important treatment option.

Coronary artery bypass surgeries are performed routinely throughout the world, savings thousands of lives and enabling patients to return to their normal lifestyles. The usual procedure in coronary bypass surgery is to use the patient's own saphenous vein or internal mammary arteries to complete the vascular reconstruction. The availability of CryoLife's cryopreserved human veins is vital for patients who do not have sufficient useable veins of their own.

CryoLife cryopreserved human saphenous veins are also used in peripheral vascular reconstruction surgeries. In those cases where a bypass is required, cryopreserved saphenous vein is an excellent option, proven to work well below the knee. Alternative synthetic graft products occlude rather quickly when placed below the knee. The availability of cryopreserved vascular tissue provides vascular surgeons with an option that can save a patient's limb.

Saphenous Vein

CryoVein^® Cryopreserved saphenous vein is a valuable vascular option for cardiac and vascular surgeons when suitable autologous vasculature is not available. When the patient's own autologous tissue may not be an option, CryoVein is the option. A dedication to quality and a supportive clinical experience has made CryoVein the sought after alternative for cardiac and vascular bypass procedures for the past 20 years.

Time is of the essence when dealing with complications of limb threatening peripheral artery disease. The commercialization availability of cryopreserved saphenous vein has given CryoLife the ability to offer surgeons and their patients the critical key to limb salvage a chance for more time. Cryopreserved saphenous vein has demonstrated exceptional performance in patients with below the knee bypass procedures where synthetic materials have historically performed poorly.

CryoVein has a long history of providing revascularization options to those with no other alternative, giving patients a chance to clear lower limb infections and regain utilization by providing what is in short supply -- time. Without the limb saving alternative offered by the cryopreserved saphenous vein, many patients only alternative is amputation. CryoVein has given surgeons and their patients the option of time when they need it most.